# EDGAR Filing Document

**Accession Number:** 0001784440
**File Stem:** 0001185185-26-001231
**Filing Date:** 2026-4
**Character Count:** 4774
**Document Hash:** 3b8c1b10c717ac2736c23d0654acc5e2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001185185-26-001231.hdr.sgml**: 20260402

**ACCESSION NUMBER**: 0001185185-26-001231

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260402

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**FILED AS OF DATE**: 20260402

**DATE AS OF CHANGE**: 20260402

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BioScience Health Innovations, Inc.
- **CENTRAL INDEX KEY:** 0001784440
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 000000000
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 333-234487
- **FILM NUMBER:** 26832770

**BUSINESS ADDRESS:**
- **STREET 1:** 2722 S WEST TEMPLE
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84115
- **BUSINESS PHONE:** 801-949-0791

**MAIL ADDRESS:**
- **STREET 1:** 2722 S WEST TEMPLE
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84115

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Nowtransit Inc
- **DATE OF NAME CHANGE:** 20190802

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) <u>April 2, 2026</u>

---

| |
|:---|
| **Bioscience Health Innovations, Inc** |
| (Exact name of registrant as specified in its charter) |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Nevada** | **333-234487** | **98-1498782** |
| (State or other jurisdiction<br> of incorporation)<br>| (Commission File Number)<br>| (IRS Employer<br> Identification No.)<br>|

---

    <br> (14857 South Concord Park Drive, Bluffdale, Utah 84065

Registrant's telephone number, including area code (801) 949-0791

<u>NOWTRANSIT INC</u> <br> (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

SECTION 5. CORPORATE GOVERNANCE AND MANAGEMENT

Item 5.02 Departure of Director and Election of Director

On April 1, 2026, Bioscience Health Innovations, Inc. (the "Company") announced that Justin Earl has resigned from the Company's Board of Directors, effective immediately. Mr. Earl's resignation was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices.

Prior to Mr. Schmidt's appointment, he has been serving as the Company's Chief Technology Officer since the Company's inception.

Dan has extensive experience in therapeutic medical devices and treatments including, Radio Frequency, Stem Cells, Laser and Ultrasound Technologies, Non-Surgical Skin Tightening and Fat Reduction. Mr. Schmidt has invested the last 26 years seeking ways to improve people's quality of life by developing and commercializing innovative healthcare products and services.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| Bioscience Health Innovations, Inc | Bioscience Health Innovations, Inc |
| A Nevada Corporation | A Nevada Corporation |
| By: | /s/ Darren Lopez |
|  | Darren Lopez<br> Chief Executive Officer |

---

Date: April 2, 2026